The Journal of dermatological treatment最新文献_第8页

The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris. 雄激素和雄激素介导的皮脂分泌的皮肤效应及其对寻常痤疮的病理生理学和治疗学意义。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-01-08 DOI: 10.1080/09546634.2023.2298878

James Q Del Rosso, Leon Kircik

{"title":"The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris.","authors":"James Q Del Rosso, Leon Kircik","doi":"10.1080/09546634.2023.2298878","DOIUrl":"https://doi.org/10.1080/09546634.2023.2298878","url":null,"abstract":"Background: The recognition of an association between the development of acne vulgaris (AV) and pubertal hormonal changes during adolescence dates back almost 100 years. Since these formative observations, a significant role of circulating hormones in the pathophysiology of AV and other cutaneous disorders has been established.Aims: This review article aims to provide an overview of clinical and preclinical evidence supporting the influences of androgens on the skin and their therapeutic importance in AV pathophysiology.Results: The cutaneous effects of hormones are attributable, to a large extent, to the influence of steroid hormones, particularly androgens, on sebocyte development and sebum production in both sexes. Androgen-mediated excess sebum production is implicated as a necessary early step in AV pathophysiology and is therefore considered an important therapeutic target in AV treatment. Although the local production and/or activity of androgens within the skin is believed to be important in AV pathophysiology, it has received limited therapeutic attention.Conclusions: We have summarized the current evidence in support of the therapeutic benefits of targeted hormonal treatment to decrease androgen-stimulated sebum production for the effective and safe treatment of AV in both male and female patients.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2298878"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial. 308 纳米准分子激光联合 0.1% 他克莫司软膏与单用 0.1% 他克莫司软膏治疗儿童局限型白癜风的有效性和安全性：随机对照试验。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2023-12-21 DOI: 10.1080/09546634.2023.2296851

Diala Alshiyab, Saleh A Ba-Shammakh, Abdulqudos Al-Fakih, Osama Tashman, Danyah Sarakbi, Firas Al-Qarqaz, Jihan Muhaidat, Ausama Atwan, Michael J Cork

{"title":"Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.","authors":"Diala Alshiyab, Saleh A Ba-Shammakh, Abdulqudos Al-Fakih, Osama Tashman, Danyah Sarakbi, Firas Al-Qarqaz, Jihan Muhaidat, Ausama Atwan, Michael J Cork","doi":"10.1080/09546634.2023.2296851","DOIUrl":"10.1080/09546634.2023.2296851","url":null,"abstract":"Objective: This study aims to assess the efficacy and safety of combining the 308-nm Excimer lamp with Tacrolimus 0.1% ointment, compared to Tacrolimus 0.1% ointment monotherapy, for treating pediatric vitiligo involving less than 10% of the body surface area.Methods: Fifty pediatric patients with vitiligo were randomly assigned to two groups. Group A received Tacrolimus 0.1% ointment twice daily and Excimer light at 308-nm twice weekly, while Group B received Tacrolimus 0.1% ointment alone, administered twice daily. Repigmentation percentages were evaluated after 30, 90, and 180 days using the rule of nine.Results: Group A exhibited a significant improvement in repigmentation, increasing from 10% after one month to 65% after six months. In contrast, Group B observed an increase from 10% to 30% over the same timeframe. The efficacy of the treatment was significantly higher in Group A at both the 3-month and 6-month follow-up points (p-value < .001). Moreover, Group A achieved notably higher repigmentation rates in the face, trunk, and lower limbs.Conclusion: The combination of Tacrolimus and the 308-nm excimer lamp yielded superior repigmentation results compared to Tacrolimus monotherapy in pediatric vitiligo patients. This combined approach may offer an effective new treatment protocol for pediatric vitiligo.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2296851"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of generalized pustular psoriasis with guselkumab. 使用古舍库单抗成功治疗泛发性脓疱型银屑病。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-03-24 DOI: 10.1080/09546634.2024.2331807

Martina Part

{"title":"Successful treatment of generalized pustular psoriasis with guselkumab.","authors":"Martina Part","doi":"10.1080/09546634.2024.2331807","DOIUrl":"10.1080/09546634.2024.2331807","url":null,"abstract":"The purpose of the article: Generalized pustular psoriasis (GPP) is a rare auto-inflammatory disease. Patients with GPP may develop life-threatening complications, including sepsis, acute renal failure, neutrophilic cholangitis, high-output congestive heart failure, acute respiratory distress syndrome and death. The therapy of GPP is very limited and the course of the disease is unpredictable.Materials and methods: We report a 60-year-old woman presenting with widespread and confluent erythematous-desquamative plaques with numerous small pustules covering almost 70% of the body surface area. Over the past years patient had undergone different types of conservative treatment regimens including topical therapy, acitretin, cyclosporin, methotrexate and long-term treatment with systemic corticosteroids. Considering the patient's overall clinical condition, we proceed to initiate the biologic therapy with guselkumab.Results: Guselkumab (anti-IL-23) in the standard dose of 100 mg was administered subcutaneously at weeks 0, 4 and followed by a maintenance dose every 8 weeks. The remission of GPP was observed already after 12 weeks of treatment. The maintenance treatment in the period of 18 months shows stable clinical response.Conclusions: Our results support the evidence that guselkumab could provide an effective therapeutic approach in the treatment of GPP.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2331807"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. 在日本的实际临床实践中，deucravacitinib 治疗中度至重度银屑病的有效性和安全性。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-02-02 DOI: 10.1080/09546634.2024.2307489

Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

{"title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.","authors":"Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.1080/09546634.2024.2307489","DOIUrl":"10.1080/09546634.2024.2307489","url":null,"abstract":"Background: Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently approved for psoriasis.Objectives: We aimed to evaluate the real-world effectiveness and safety of deucravacitinib for psoriasis.Methods: We analyzed 33 Japanese patients with psoriasis (23 with plaque psoriasis, eight with psoriatic arthritis, and two with erythrodermic psoriasis) from January 2023 to October 2023. All patients received deucravacitinib 6 mg daily until week 16.Results: At week 8, 12, or 16, the achievement rate of PASI 75 was 60.9%, 73.9%, or 78.3%, that of PASI 90 was 13.0%, 39.1%, or 52.2%, that of PASI 100 was 0%, 8.7%, or 13.0%, that of absolute PASI ≤2 was 34.8%, 65.2%, or 78.3%, respectively. The achievement rate of dermatology life quality index 0/1 at week 16 was 42.9%. Fourteen patients (42%) complained pruritus. Peak pruritus-numerical rating scale in patients with pruritus decreased by median [interquartile] 71.4 [50-80] % of baseline at week 2. Adverse events occurred in 18.2% of patients, which were mild and manageable.Conclusions: Deucravacitinib for patients with psoriasis was well-tolerated and gave favorable therapeutic effects in the real-world practice. Deucravacitinib treatment rapidly reduced pruritus.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2307489"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular mechanisms and drug therapy of metabolism disorders in psoriasis. 银屑病代谢紊乱的分子机制和药物治疗。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-07-16 DOI: 10.1080/09546634.2024.2375580

Yanyang Liang, Ying Wang, Aihong Peng, Junqin Li, Kaiming Zhang

{"title":"Molecular mechanisms and drug therapy of metabolism disorders in psoriasis.","authors":"Yanyang Liang, Ying Wang, Aihong Peng, Junqin Li, Kaiming Zhang","doi":"10.1080/09546634.2024.2375580","DOIUrl":"https://doi.org/10.1080/09546634.2024.2375580","url":null,"abstract":"Psoriasis is a prevalent skin disease affecting approximately 1%-3% of the population and imposes significant medical, social and economic burdens. Psoriasis involves multiple organs and is often complicated with obesity, diabetes, dyslipidemia, and hypertension. Because of the benefits of lipid-lowering agents and antidiabetic medications for psoriasis, metabolic abnormalities possibly play a pathogenic role in psoriasis.This review focuses on the impacts of a variety of metabolic disorders on psoriasis and the underlying mechanisms.In psoriasis, enhanced glycolysis, glutamine metabolism and altered fatty acid composition in the psoriatic lesion and plasma result in the excessive proliferation of keratinocytes and secretion of inflammatory cytokines. Altered metabolism is associated with the activation of MTORC signaling pathway and transcription factors such as HIF and S6K1. Therefore, MTORC1 can be a target for the treatment of psoriasis. Additionally, there are diabetes drugs and lipid-lowering drugs including TZDs, GLP-1 RAs, Metformin, statins and fibrates, which improve both metabolic levels and psoriasis symptoms.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2375580"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilizing artificial intelligence technology with emotional intelligence in clinical office visits. 在临床门诊中利用人工智能技术和情感智能。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-07-23 DOI: 10.1080/09546634.2024.2374500

Robin C Yi, Hannah Y Gantz, Steven R Feldman

引用次数: 0

Botanical extract combined with minoxidil improve hidrotic ectodermal dysplasia caused by p.G11R mutations: a case report. 植物提取物与米诺地尔联合治疗 p.G11R 突变引起的潮解性外胚层发育不良：病例报告。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-07-11 DOI: 10.1080/09546634.2024.2378163

Shiyi Zhong, Chuhan Huang, Mingyue Zhuang, Qingwu Liu, Ziyuan Tian, Dingquan Yang

{"title":"Botanical extract combined with minoxidil improve hidrotic ectodermal dysplasia caused by p.G11R mutations: a case report.","authors":"Shiyi Zhong, Chuhan Huang, Mingyue Zhuang, Qingwu Liu, Ziyuan Tian, Dingquan Yang","doi":"10.1080/09546634.2024.2378163","DOIUrl":"10.1080/09546634.2024.2378163","url":null,"abstract":"Purpose: We aim to explore a potential treatment strategy for hair loss.Materials and methods: A male 6-year-old child was diagnosed with hidrotic ectodermal dysplasia 2 (HED2) caused by GJB6 (p.G11R) mutations. He presented at our clinic with diffuse thinning and fine and brittle hair since birth. Additionally, the child exhibited abnormal development of teeth, fingernails, and toenails. The condition of the child's hair had not improved significantly with age. He was treated with botanical extracts combined with Minoxidil.Results: After one and a half months of treatment, the patient showed remarkable hair growth.Conclusions: Our team has previously used botanical extracts in combination for the treatment of autosomal recessive wooly hair in children. In the present case, treatment with botanical extract combined with minoxidil was found to be equally efficacious. This case report provides valuable information for future studies on the use of botanical extracts in treating hair loss, as well as a safe and effective potential treatment strategy for children with congenital alopecia.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2378163"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia. 用于银屑病治疗的生物疗法的处方模式和持续性：沙特阿拉伯的一项回顾性队列研究。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-08-05 DOI: 10.1080/09546634.2024.2386973

Ahmad Alamer, Wejdan Alyazidi, Saad Aldosari, Fatimah Mobarki, Sarah Almakki, Abdullah Alahmari, Mukhtar Alomar, Ziyad Almalki, Tuqa Alkaff, Mohammad Fazel

{"title":"Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia.","authors":"Ahmad Alamer, Wejdan Alyazidi, Saad Aldosari, Fatimah Mobarki, Sarah Almakki, Abdullah Alahmari, Mukhtar Alomar, Ziyad Almalki, Tuqa Alkaff, Mohammad Fazel","doi":"10.1080/09546634.2024.2386973","DOIUrl":"https://doi.org/10.1080/09546634.2024.2386973","url":null,"abstract":"Background: Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives: To identify physicians' prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation.Methods: We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months.Results: A total of 151 patients received adalimumab (n = 89), etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability.Conclusion: This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2386973"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141895124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis. 各种准分子激光（EL）联合疗法治疗白癜风的比较：系统综述和网络荟萃分析。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-01-17 DOI: 10.1080/09546634.2024.2302064

ChanXiu Li, Yue Hu, ZengYi Mu, Lei Shi, Xiao Sun, XinYue Wang, YaPing Wang, XinHong Li

{"title":"Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis.","authors":"ChanXiu Li, Yue Hu, ZengYi Mu, Lei Shi, Xiao Sun, XinYue Wang, YaPing Wang, XinHong Li","doi":"10.1080/09546634.2024.2302064","DOIUrl":"10.1080/09546634.2024.2302064","url":null,"abstract":"Aim: This study aimed to compare the efficacy and safety of excimer laser (EL)-based combination regimens in improving repigmentation.Methods: A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, and Embase on July 1, 2023, to include randomized controlled trials of EL combination treatments for vitiligo that met the criteria. The primary outcome measure was a repigmentation rate ≥ 75%, and the secondary outcome measures were a repigmentation rate of ≤ 25% and adverse events.Results: Eleven studies involving 348 patients were included. Network Meta-Analysis showed that EL combined with antioxidants (SUCRA = 98.8%), EL combined with calcipotriol (SUCRA = 59.8%) and EL combined with tacalcitol (SUCRA = 59.6%) were the three optimal interventions achieving repigmentation rates ≥ 75%. EL alone (SUCRA = 77.6%), EL combined with tacalcitol (SUCRA = 61.7%) and EL combined with antioxidants (SUCRA = 57.2%) were the three interventions with the highest rates of treatment failure. Adverse events in all groups mainly included erythema, burning sensation and hyperpigmentation. Based on the results of the current study, EL combination therapies were safe with mild adverse events.Conclusion: EL combined with antioxidants was the preferred regimen for vitiligo, whereas EL alone was the regimen with the highest rate of treatment failure in vitiligo.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2302064"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

The Journal of dermatological treatment Pub Date : 2024-12-01 Epub Date: 2024-01-19 DOI: 10.1080/09546634.2024.2302710

引用次数: 0